KCM
NAGE

Knoll Capital Management’s Niagen Bioscience NAGE Stock Holding History

Knoll Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-45,019
Closed -$154K – 19
2018
Q4 		$154K Sell
45,019
-2,847
-6% -$9.89K 0.18% 14
2018
Q3 		$192K Hold
47,866
– – 0.16% 15
2018
Q2 		$178K Buy
+47,866
New +$182K 0.15% 16

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

Knoll Capital Management's NAGE Position: Q1 2019 in Review

Knoll Capital Management sold out of Niagen Bioscience (NAGE) in Q1 2019, closing a stake of 45,019 shares — an estimated $154K sold.

Knoll Capital Management first reported a position in NAGE in Q2 2018 and held it in 3 quarters. The position peaked at $192K in Q3 2018. 58 funds tracked by Wall St. Rank hold NAGE as of Q1 2019.

  • Knoll Capital Management reported no remaining Niagen Bioscience position as of Q1 2019 after selling out during the quarter.
  • Knoll Capital Management sold 45,019 Niagen Bioscience shares in Q1 2019, an estimated $154K.
  • Knoll Capital Management first reported a position in Niagen Bioscience in Q2 2018 and held it in 3 quarters.
  • Knoll Capital Management's Niagen Bioscience position peaked at $192K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2019.

Based on Knoll Capital Management's 13F filing for Q1 2019, filed 15 May 2019.